

**UBE2L3 Antibody (C-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP2117b****Specification**

---

**UBE2L3 Antibody (C-term) Blocking Peptide - Product Information**

Primary Accession [P68036](#)  
Other Accession [NP\\_003338](#)

**UBE2L3 Antibody (C-term) Blocking Peptide - Additional Information**

**Gene ID** 7332

**Other Names**

Ubiquitin-conjugating enzyme E2 L3, L-UBC, Ubch7, Ubiquitin carrier protein L3,  
Ubiquitin-conjugating enzyme E2-F1, Ubiquitin-protein ligase L3, UBE2L3, UBCE7, UBCH7

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP2117b](/product/products/AP2117b) was selected from the C-term region of human UBE2L3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**UBE2L3 Antibody (C-term) Blocking Peptide - Protein Information**

**Name** UBE2L3

**Synonyms** UBCE7, UBCH7

**Function**

Ubiquitin-conjugating enzyme E2 that specifically acts with HECT-type and RBR family E3 ubiquitin-protein ligases. Does not function with most RING-containing E3 ubiquitin-protein ligases because it lacks intrinsic E3-independent reactivity with lysine: in contrast, it has activity with the RBR family E3 enzymes, such as PRKN, RNF31 and ARIH1, that function like RING-HECT hybrids. Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes 'Lys-11'-linked polyubiquitination. Involved in the selective degradation of short-lived and abnormal proteins. Down-regulated during the S-phase it is involved in progression through the cell cycle. Regulates nuclear hormone receptors transcriptional activity.

May play a role in myelopoiesis.

**Cellular Location**

Nucleus. Cytoplasm

**Tissue Location**

Ubiquitous, with highest expression in testis.

**UBE2L3 Antibody (C-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**UBE2L3 Antibody (C-term) Blocking Peptide - Images****UBE2L3 Antibody (C-term) Blocking Peptide - Background**

The modification of proteins with ubiquitin is an important cellular mechanism for targeting abnormal or short-lived proteins for degradation. Ubiquitination involves at least three classes of enzymes: ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s) and ubiquitin-protein ligases (E3s). UBE2L3 is a member of the E2 ubiquitin-conjugating enzyme family. This enzyme is demonstrated to participate in the ubiquitination of p53, c-Fos, and the NF-kB precursor p105 in vitro.

**UBE2L3 Antibody (C-term) Blocking Peptide - References**

Moynihan, T.P., et al., Genomics 51(1):124-127 (1998). Moynihan, T.P., et al., Mamm. Genome 7(7):520-525 (1996). Nuber, U., et al., J. Biol. Chem. 271(5):2795-2800 (1996). Robinson, P.A., et al., Mamm. Genome 6(10):725-731 (1995). Ardley, H.C., et al., Biochim. Biophys. Acta 1491 (1-3), 57-64 (2000).